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Background: The cooperation between phorbol 12-myristate 13-acetate induced protein 1 (NOXA) and myeloid
cell leukemia 1 (MCL1) is critical in the intrinsic apoptotic pathway. Human papillomavirus 16 (HPV16), by inducing
p53 and pRb-E2F degradation, may play an essential role in development of squamous cell carcinoma of the head
and neck (SCCHN) through NOXA-MCL1 axis-mediated apoptosis. Therefore, genetic variants of NOXA and MCL1
may modify the SCCHN risk associated with HPV16 seropositivity.
Methods: HPV16 serology was obtained by immunoadsorption assay. Four functional SNPs in the promoter
of NOXA (rs9957673, rs4558496) and MCL1 (rs9803935, rs3738485) were genotyped for 380 cases and 335
frequency-matched cancer-free controls of non-Hispanic whites.
Results: Associations between the four polymorphisms and SCCHN risk were not significant, while we observed a
significantly joint effect on SCCHN risk between the polymorphisms and HPV16 seropositivity. Notably, this effect
modification was particularly pronounced for oropharyngeal cancer in subgroups including never smokers, never
drinkers and younger subjects.
Conclusions: Our results suggested that polymorphisms of NOXA and MCL1 may modify the risk of
HPV16-associated oropharyngeal cancer. The further identification of population subgroups at higher risk
provides evidence that HPV-targeting treatment may help benefit SCCHN. However, larger studies are
needed to validate our findings.
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Apoptosis has been implicated in the development of
various human cancers, including squamous cell carcin-
oma of the head and neck (SCCHN). Growing evidence
suggests that suboptimal apoptotic capacity leads to fail-
ure in responding to unfavorable stimuli and eliminating
potentially neoplastic clones, which may cause accumu-
lation of cells with cancer-prone mutations and therefore
result in cancer susceptibility [1]. The Bcl-2 family pro-
teins, as well as cooperation among their anti- and pro-* Correspondence: gli@mdanderson.org
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reproduction in any medium, provided the orapoptotic subgroup members, control the balance be-
tween death (apoptosis) and survival of cells, and conse-
quently may alter the risk of cancers [2-5]. As one of the
p53 downstream targets, the pro-apoptotic Bcl-2 sub-
family protein NOXA (Latin for damage; HUGO desig-
nation is phorbol 12-myristate 13-acetate induced
protein 1, PMAIP1) is recognized as a crucial switch that
connects apoptotic signals with the anti-apoptotic sub-
family proteins. Indeed, the NOXA can exclusively bind
to the anti-apoptotic subfamily protein MCL1 (myeloid
cell leukemia 1) and consequently initiate apoptosis by
both sequestering MCL1 and promoting MCL1 degrad-
ation [4,6,7]. Evidence from in vitro and in vivo studies
indicates that NOXA deficiency or MCL1 over-
expression may protect cells from apoptosis in a p53-
dependent or independent manner, whereas NOXAtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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help restore sensitivity to apoptosis [7-9]. The role of
NOXA-MCL1 axis-mediated apoptosis in cancer risk is
not fully understood. High levels of MCL1 were found
in solid human tumors and cell lines derived from
human leukemia or lymphomas [10]; furthermore, stud-
ies in vivo showed that knockdown of NOXA or co-
expression of MCL1 and oncogene MYC can signifi-
cantly accelerate the development of tumors such as
lymphoma or leukemia [10-12]. This implies that NOXA
and MCL1 may be extensively involved in the tumori-
genesis of different origins. However, whether NOXA
and MCL1 play a role in the etiology of head and neck
cancer remains unclear.
As the eighth most common cancer worldwide,
SCCHN accounts for nearly 3% of all incident malignan-
cies in the U.S. with approximately 24,000 cases of oral
cavity cancer, 13,000 of oropharyngeal cancer, and
12,000 of laryngeal cancer [13]. Studies have demon-
strated that SCCHN is a heterogeneous group of distinct
subtypes with distinct risk factors. In addition to the
most well defined risk factors, tobacco smoking and al-
cohol drinking, the infection of human papillomavirus
(HPV), 90% of which is the oncogenic type 16, is re-
cently reported to be detectable in approximately one
fourth to one third of SCCHN [14,15], and recognized
as one of the most potentially contributive risk factors
for SCCHN arising at the oropharyngeal site [16-22].
The major HPV oncoproteins E6 and E7 cooperate in
HPV-related carcinogenesis. By E6-induced p53 degrad-
ation and E7-induced pRb-E2F degradation, HPV infec-
tion may possibly cause deregulation of p53-pathway
and pRb-E2F-pathway, respectively, consequently result-
ing in tumorigenesis [23-25]. The fact that only a small
proportion of individuals with HPV infection developed
SCCHN suggests that genetic factors may potentially
play a role in susceptibility to HPV-associated SCCHN.
Our previous studies also have shown that genetic var-
iants of genes involved in the p53 pathway, such as p53,
p73 and MDM2, can modify the association of SCCHN
risk with HPV seropositivity [26-28]. However, there
have been no published population studies investigating
the association between functional polymorphisms in
the NOXA or MCL1 promoter and the risk of HPV-
associated SCCHN.
Cumulating evidence indicates that HPV E6/E7 may
regulate the expression of NOXA and MCL1 in different
cancer cells. Inhibition of either E6 or E6-associated pro-
tein can trigger a slight increase of NOXA levels, despite
inducing a prominent accumulation of p53, in HeLa
human cervix cancer cell [29]. More recently, Cheng
et al. [30] proved that, through the PI3K pathway, MCL1
expression levels are up-regulated in HPV E6- and E7-
expressing and HPV16-infected cancer cells; andconsistently, MCL1 expression is significantly reduced
by knockdown of HPV E6 or E7 expression [31]. In
addition, the promoter regions of both NOXA and
MCL1 contain an array of confirmed or putative tran-
scription factor binding sites, such as p73, E2F1, and
STAT response elements [7,32]. Since both NOXA and
MCL1 can be transcription-regulated, we hypothesized
that HPV infection may deregulate NOXA-MCL1 axis-
mediated apoptosis and subsequently affect the risk of
SCCHN.
To test this hypothesis, we genotyped the putatively
functional polymorphisms in the NOXA and MCL1 pro-
moters, and aimed to determine whether these genetic
variants can, independently or jointly with HPV16 sero-
positivity, influence the risk of SCCHN, especially for
those arising at the oropharyngeal site.
Methods
Patients and control samples
Details of this SCCHN case–control study population
were previously described elsewhere [27]. Briefly, all
histopathologically confirmed incident SCCHN patients
were recruited consecutively as part of an ongoing mo-
lecular epidemiology study of SCCHN at the Head and
Neck Surgery Clinic at The University of Texas M.D.
Anderson Cancer Center between May 1996 and May
2002. The response rate of eligible patients who signed
an informed agreement for participating in the study
was approximately 95%. Excluded patients included
those with second primary tumors; primary tumors of
the sinonasal tract and nasopharynx; primary tumors
outside the upper aerodigestive tract; cervical metastases
of unknown origin; and histopathologic diagnoses of
tumors other than squamous cell carcinoma, as well as
patients with known immune symptoms, who had
received recent blood transfusions within the last
6 months, or who were receiving immunosuppressive
therapy. Finally, 380 non-Hispanic white SCCHN
patients in whom HPV serology had been performed
were included in this study.
Controls were recruited from a pool of cancer-free sub-
jects from the hospitals in Houston metropolitan area. In
this cancer-free control pool, a short questionnaire was
used to determine each individual’s willingness to partici-
pate in the study before he or she was interviewed and
asked to provide demographic and epidemiologic informa-
tion including age, sex, ethnicity, smoking history, and al-
cohol consumption. Exclusion criteria for the control
group included having had cancer previously, having
known immune symptoms, received blood transfusions
within the last 6 months, or were currently receiving im-
munosuppressive therapy. Approximately 78% of eligible
subjects responded to the survey. As a result, 335 cancer-
free control individuals were selected from the pool of
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years), gender, ethnicity, and smoking and alcohol drink-
ing status. These variables were further adjusted in later
multivariable logistic regression analyses to control for any
residual confounding.
The “smoker” and “drinker” are defined in consistent
with CDC report [33] and our previously published
studies [26-28]. Briefly, “ever smokers” were those who
had smoked more than 100 cigarettes in their lifetime,
and the rest were “never smokers”; “ever drinkers” were
those who drank alcoholic beverages at least once per
week lasting for more than one year, and others were
“never drinkers”. After a written informed consent was
given, each individual provided a one-time 30-ml blood
sample collected in heparinized tubes. The research
protocol was approved by the institutional review board
of M.D. Anderson Cancer Center.
Selection and genotyping of candidate SNPs
The NCBI dbSNP database (http://www.ncbi.nlm.nih.gov/
projects/SNP) build 131 and bioinformatics tool (http://
manticore.niehs.nih.gov/snpfunc) were used to identify
potentially functional SNPs in NOXA andMCL1 promoter
regions. We first scanned for all reported common SNPs
(minor allele frequency, MAF> 0.05 in CEU population)
that are predicted to affect the function of binding to tran-
scription factors and located in the coding region or in the
5’-untranslated region known as the transcriptional regu-
latory region in the upstream of the start codon (from
−2000 to +1), as well as for SNPs located in 3’-UTR in the
downstream of coding region (+1 kb downstream) for po-
tential miRNA binding sites; and then the linkage disequi-
librium (LD) between pro-target SNPs was assessed by
using the public HapMap SNP database (http://www.
hapmap.org). As a result, of the 64 SNPs reported in
NOXA and 91 SNPs reported in MCL1, there were no
common non-synonymous SNPs located in the coding
regions and no common SNPs located in the 3’-UTR that
may potentially alter the miRNA-binding profile; finally,
there were two SNPs in the NOXA promoter region
(rs9957673, rs4558496) and two SNPs in the MCL1 pro-
moter region (rs9803935, rs4558496) predicted to be po-
tentially functional and selected for genotyping. Genomic
DNA obtained from the buffy coat of whole blood samples
was extracted by the Qiagen DNA blood mini kit (Valen-
cia, CA). Genotyping of NOXA andMCL1 polymorphisms
was performed by using the TaqMan assay, and the
pre-designed probes were purchased from Applied Biosys-
tems (ABI, Foster City, CA, USA). The pre-designed
SNP genotyping assay IDs are C_30385519_20 for
rs9957673, C_27902210_10 for rs4558496, C_1545306_10
for rs9803935, and C_27471449_10 for rs3738485. PCRs
were run in a final volume of 5 μl per reaction, containing
10 ng genomic DNA, TaqMan Universal Master Mix,80×SNP Genotyping Assay Mix, and DNAse-free water.
Four blank and positive controls and three random
repeated samples were included in each plate for the
genotyping assay quality control. The samples were geno-
typed by using the ABI 7900HT Sequence Detection Sys-
tem and Prism SDS 2.3 software.
HPV16 serologic testing
In current study, a standard enzyme-linked immunoad-
sorption assay, as previously described, was used to
identify the HPV16 L1 seropositivity [34]. The plasma
HPV16 L1 capsid protein antibody was tested by using
HPV16 L1 virus-like particles generated from recombin-
ant baculovirus-infected insect cells. The HPV16 L1
seropositivity cutoff level was determined by using a
standard pooled serum known to be at the cutoff point
for HPV16 L1 seropositivity in a previous study [34].
Samples within 15% of the cutoff point were tested two
more times, only those defined as positive in all three
tests were considered positive. To avoid the heparin’s
interfering for binding, plasma samples were treated
with heparinase I before testing. No discernible reaction-
difference was detected between the serum samples and
the heparinized plasma samples obtained from three
individuals. For quality control, 10% of the samples were
randomly chosen for retesting and 100% concordance
was observed in the repeat tests.
Statistical analysis
The differences in distributions of selected variables,
HPV16 serological status and NOXA and MCL1 geno-
types between cases and controls were examined by
using the χ2 test. Odds ratios (OR) and their 95% confi-
dence intervals (CI) were calculated to evaluate the asso-
ciation of NOXA and MCL1 genotypes and HPV16
seropositivity with the risk of SCCHN in both univariate
and multivariable logistic regression models. The joint
effects of examined genotypes and HPV16 seropositivity
on risk of SCCHN were evaluated, which were further
assessed in subgroups stratified by tumor sites, age,
smoking and drinking status. The “linkage disequilib-
rium” (LD) procedure in the HelixTree v7.3.0 (Golden
Helix Inc., Bozeman, MT, USA) was used to estimate the
LD by means of LD coefficients (D’) and the r2. All of
the statistical analyses were performed by using Statis-
tical Analysis System software (Version 9.1; SAS Insti-
tute, Cary, NC), and two-sided P value< 0.05 was
considered statistically significant.
Results
Demographic and risk factors for study subjects
We originally recruited 380 eligible cases and 335 con-
trols of non-Hispanic whites in this study, of these sub-
jects, eight cases and twenty controls failed in the
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were included in the final genotyping analysis. The
demographic characteristics and distribution of known
SCCHN risk factors of the study population are sum-
marized in Table 1. The cases and controls appeared to
be adequately frequency-matched for sex, age, smoking
status, and alcohol use. However, we found that cases
were much more likely than controls to be HPV16 sero-
positive (P< 0.0001). HPV16 seropositivity was signifi-
cantly associated with increased risk of oropharyngeal
cancer (adjusted OR= 5.7; 95% CI, 3.6-8.9) but not
SCCHN at non-oropharyngeal sites (adjusted OR= 0.7;
95% CI, 0.4-1.3).
Joint effects of gene variants and HPV16 seropositivity on
the risk of SCCHN
The distributions of NOXA and MCL1 genotypes and
their associations with risk of SCCHN are shown in
Table 2. The frequencies of all tested SNPs among con-
trols were in agreement with Hardy-Weinberg equilib-
rium (P= 0.069 for rs9957673, P= 0.139 for rs4558496,
P= 0.898 for rs9803935, and P= 0.871 for rs3738485).
Because the LD evaluation for the SNPs in NOXA or
MCL1 is unavailable in the HpaMap database, weTable 1 Frequency distribution of demographic and risk
factors in SCCHN cases and controls
Characteristics Patients (n = 380) Controlsa (n = 335) P
valuebNo. % No. %
Age (years) 0.526
<40 32 8.4 27 8.1
41–55 142 37.4 109 32.5
56–70 159 41.8 157 46.9
>70 47 12.4 42 12.5
Sex 0.100
Male 285 75.0 269 80.3
Female 95 25.0 66 19.7
Ethnicity
Non-Hispanic white 380 100.0 335 100.0
Tobacco smoking 0.588
Ever 278 73.2 239 71.3
Never 102 26.8 96 28.7
Alcohol drinking
Ever 296 77.9 240 71.6 0.054




a The controls were frequency matched to the patients on the factors shown
in this table.
b Two-sided χ2 test.calculated the LD values for the SNPs studied. The
NOXA rs9957673 and NOXA rs4558496 were in low
linkage (D’= 0.901, r2 = 0.04), while the MCL1 rs9803935
and MCL1 rs3738485 were in high linkage (D’= 0.98,
r2 = 0.95). There was no significant association observed
between the putatively functional SNPs and the risk of
overall or subtypes of the SCCHN (oropharyngeal or
non-oropharyngeal cancers). However, we found that
the variants of both NOXA and MCL1 genes modified the
association between the HPV16 seropositivity and the risk
of SCCHN.
As summarized in Table 3, we estimated the joint
effects of the HPV16 seropositivity and genotypes of
NOXA and MCL1 on SCCHN risk. By using the group
with the NOXA rs9957673 CC genotype and HPV16
seronegativity as reference, those with the CT/TT geno-
types and HPV16 seronegativity did not show associ-
ation with increased SCCHN risk (OR= 1.0; 95%
CI,0.7-1.4); however, those with the CC genotype and
HPV16 seropositivity had a 2.4-fold increased SCCHN
risk (95% CI, 1.4-4.0), and those with the CT/TT geno-
types and HPV16 seropositivity had a 3.6-fold increased
SCCHN risk (95% CI,1.9-6.8). Similarly, compared with
those with the NOXA rs4558496 TT genotype and
HPV16 seronegativity, those with the TT genotype and
HPV16 seropositivity had an OR of 2.7 (95% CI, 1.4-5.4),
and those with both TG/GG genotypes and HPV16 sero-
positivity had an OR of 2.8 (95% CI, 1.4-5.5). For the two
linked SNPs in MCL1 promoter, when subjects with the
MCL1 rs9803935 GG/GT genotypes and HPV16 sero-
negativity as the reference group, those with the TT
genotype and HPV16 seronegativity had an OR of 0.8
(95% CI, 0.5-1.2), those with the GG/GT genotypes and
HPV16 seropositivity had an OR of 2.1 (95% CI, 1.3-3.3),
and those with the TT genotype and HPV16 seropositiv-
ity had an OR of 8.1 (95% CI, 2.8-23.7). The similar
results were also observed for MCL1 rs3738485 poly-
morphism (Table 3).
We further analyzed the joint effects between the
SNPs and HPV16 seropositivity on the risks of both oro-
pharyngeal and non-oropharyngeal cancers. We found
that effect modification of the NOXA and MCL1 SNPs
on risk of HPV-associated cancers was evident for oro-
pharyngeal but not for SCCHN at non-oropharyngeal
sites (Table 3).
Stratification of the joint effects of NOXA and MCL1
variants and HPV16 seropositivity on oropharyngeal
cancer risk
Since the modification effect of NOXA and MCL1 var-
iants on SCCHN risk associated with HPV16 seroposi-
tivity was particularly evident for oropharyngeal cancers,
we further evaluated the effect modification of the var-
iants on risk of oropharygeal cancer associated with
Table 2 Associations between NOXA and MCL1 genotypes and SCCHN risk
Gene Varianta Control Overall (n = 372) Oropharynx (n= 184) Non-oropharynx (n = 188)
n = 315 (%) Patients (%) ORb (95%CI) Patients (%) ORb (95%CI) Patients (%) ORb (95%CI)
NOXA rs9957673
CC 216 (68.6) 246 (66.1) 1.0 118 (64.1) 1.0 128 (68.1) 1.0
CT 95 (30.2) 115 (30.9) 1.0 (0.7-1.4) 60 (32.6) 1.1 (0.7-1.7) 55 (29.3) 1.1 (0.9-1.6)
TT 4 (1.3) 11 (3.0) 2.3 (0.7-7.4) 6 (3.3) 1.9 (0.4-8.1) 5 (2.7) 2.0 (0.5-8.3)
P trend =0.300 P trend = 0.180 P trend = 0.689
CT + TT 99 (31.4) 126 (33.9) 1.1 (0.8-1.5) 66 (35.9) 1.1 (0.7-1.7) 60 (31.9) 1.1 (0.7-1.6)
NOXA rs4558496
TT 216 (68.6) 253 (69.1) 1.0 121 (65.8) 1.0 136 (72.3) 1.0
TG 85 (27.5) 107 (29.3) 1.0 (0.7-1.5) 61 (33.2) 1.23 (0.8-1.9) 48 (25.5) 0.9 (0.6-1.3)
GG 14 (4.3) 6 (1.6) 0.4 (0.2-1.1) 2 (1.1) 0.34 (0.1-1.6) 4 (2.1) 0.4 (0.1-1.4)
P trend =0.411 P trend = 0.913 P trend = 0.224
TG+GG 99 (31.4) 115 (30.9) 1.0 (0.7-1.3) 63 (34.3) 1.1 (0.7-1.7) 52 (27.7) 0.8 (0.5-1.2)
MCL1 rs9803935
GG 95 (30.2) 127 (34.1) 1.0 65 (35.3) 1.0 62 (33.0) 1.0
GT 157 (59.8) 169 (45.4) 0.8 (0.6-1.2) 77 (41.9) 0.8 (0.5-1.3) 92 (48.9) 0.9 (0.6-1.4)
TT 63 (20.0) 76 (20.4) 0.9 (0.6-1.5) 42 (22.8) 1.1 (0.6-1.8) 34 (18.1) 0.9 (0.6-1.6)
P trend =0.516 P trend = 0.726 P trend = 0.463
GG+GT 252 (80.0) 296 (79.6) 1.0 142 (77.2) 1.0 154 (81.9) 1.0
TT 63 (20.0) 76 (20.4) 1.0 (0.7-1.5) 42 (22.8) 1.2 (0.7-1.9) 34 (18.1) 1.0 (0.6-1.6)
MCL1 rs3738485
GG 93 (29.5) 128 (34.4) 1.0 65 (35.3) 1.0 63 (33.5) 1.0
GC 155 (49.2) 168 (45.2) 0.8 (0.6-1.2) 77 (41.9) 0.8 (0.5-1.3) 91 (47.4) 0.9 (0.6-1.3)
CC 67 (21.3) 76 (20.4) 0.9 (0.6-1.3) 42 (22.8) 1.0 (0.6-1.7) 34 (18.1) 0.9 (0.5-1.5)
P trend =0.298 P trend = 0.528 P trend = 0.271
GG+GC 248 (78.7) 296 (79.6) 1.0 142 (77.2) 1.0 154 (81.9) 1.0
CC 67 (21.3) 76 (20.4) 1.0 (0.7-1.4) 42 (22.8) 1.1 (0.7-1.8) 34 (18.1) 0.9 (0.6-1.5)
a The observed genotype frequencies among the controls were in agreement with Hardy-Weinberg equilibrium (P=0.069 for rs9957673, P=0.139 for rs4558496,
P=0.898 for rs9803935, P=0.871 for rs3738485).
b ORs were adjusted for age, sex, smoking, drinking, and HPV16 serology.
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tus and age (Table 4, 5, 6).
For each polymorphism, the modifying effects on the
risk of oropharyngeal cancer associated with HPV16
seropositivity were much stronger in never smokers than
in ever smokers (Table 4) and in never drinkers than in
ever drinkers (Table 5). Additionally, in the age-stratified
analysis (stratified by the mean age of controls), the
modifying effects of NOXA and MCL1 variants on risk
of oropharyngeal cancer associated with HPV16 sero-
positivity was more pronounced among younger subjects
(aged ≤ 58 year) than among older subjects (aged> 58
year) (Table 6).
Discussion
In this study, we did not observe significant main
effects of the SNPs in the promoter regions of NOXAand MCL1 genes on the risk of SCCHN. However, all
tested polymorphisms showed effect modification on
risk of HPV-associated SCCHN, particularly for oro-
pharyngeal cancer patients who were never smokers,
never drinkers, and younger subjects (aged ≤ 58 year).
Although these data suggest a potential joint effect be-
tween HPV16 infection and NOXA or MCL1 poly-
morphisms, larger studies are still needed to validate
our findings.
The deregulation of apoptosis is known as an import-
ant cause of neoplasia. In the intrinsic apoptotic path-
way, apoptosis is usually mediated by cooperation
among proapoptotic members (such as NOXA) and
antiapoptotic members (such as MCL1) of the Bcl-2
family proteins. Differing from other BH3-only mem-
bers, such as PUMA, NOXA usually executes its proa-
poptotic function by exclusively binding to MCL1, A1 or
Table 3 Joint effects between HPV16 seropositivity and NOXA and MCL1 genotypes on risk of SCCHN
HPV16 Serology Gene Variant Control Overall (n = 372) Oropharynx (n = 184) Non-oropharynx (n= 188)
n = 315 (%) Patients (%) ORa (95%CI) Patients (%) ORa (95%CI) Patients (%) ORa (95%CI)
NOXA rs9957673
- CC (Ref.) 189 (60.0) 187 (50.3) 1.0 68 (37.4) 1.0 119 (63.3) 1.0
- CT + TT 85 (27.0) 83 (22.3) 1.0 (0.7-1.4) 31 (17.0) 1.0 (0.6-1.7) 52 (27.7) 1.0 (0.7-1.5)
+ CC 27 (8.6) 59 (15.9) 2.4 (1.4-4.0) 50 (27.2) 4.8 (2.8-8.3) 9 (4.8) 0.5 (0.2-1.2)
+ CT + TT 14 (4.4) 43 (11.6) 3.6 (1.9-6.8) 35 (19.0) 7.1 (3.6-14.3) 8 (4.3) 1.1 (0.4-2.8)
P trend =0.017 P trend< 0.001 P trend = 0.744
NOXA rs4558496
- TT (Ref.) 188 (59.7) 188 (50.8) 1.0 66 (36.3) 1.0 123 (65.4) 1.0
- TG+GG 86 (27.3) 86 (21.8) 0.9 (0.6-1.4) 33 (17.9) 1.1 (0.7-1.8) 48 (25.5) 0.8 (0.5-1.3)
+ TT 28 (8.9) 68 (18.3) 2.7 (1.7-4.5) 55 (29.9) 5.6 (3.2-9.6) 13 (6.9) 0.8 (0.4-1.7)
+ TG+GG 13 (4.1) 34 (9.1) 2.8 (1.4-5.5) 30 (16.3) 6.1 (3.0-12.6) 4 (2.1) 0.4 (0.1-1.4)
P trend =0.086 P trend< 0.001 P trend = 0.197
MCL1 rs9803935
- GG+GT (Ref.) 215 (68.2) 224 (60.2) 1.0 81 (44.0) 1.0 143 (76.1) 1.0
- TT 59 (18.7) 46 (12.4) 0.8 (0.5-1.2) 18 (9.8) 0.8 (0.5-1.5) 28 (14.9) 0.8 (0.5-1.3)
+ GG+GT 37 (11.8) 72 (19.4) 2.1 (1.3-3.3) 61 (33.2) 4.3 (2.6-7.1) 11 (5.9) 0.5 (0.2-1.0)
+ TT 4 (1.3) 30 (8.1) 8.1 (2.8-23.7) 24 (13.0) 14.9 (5.0-44.6) 6 (3.2) 2.7 (0.7-9.8)
P trend =0.030 P trend< 0.001 P trend = 0.317
MCL1 rs3738485
- GG+GC (Ref.) 212 (67.3) 223 (60.0) 1.0 81 (44.0) 1.0 142 (75.5) 1.0
- CC 62 (19.7) 47 (12.6) 0.8 (0.5-1.2) 18 (9.8) 0.8 (0.4-1.4) 29 (15.4) 0.8 (0.5-1.3)
+ GG+GC 36 (11.4) 73 (19.6) 2.2 (1.4-3.4) 61 (33.2) 4.4 (2.7-7.2) 12 (6.4) 0.5 (0.3-1.1)
+ CC 5 (1.6) 29 (7.8) 6.3 (2.4-16.7) 24 (13.0) 11.7 (4.3-32.0) 5 (2.7) 1.9 (0.5-6.8)
P trend =0.071 P trend< 0.001 P trend = 0.189
a ORs were adjusted for age, sex, and tobacco smoking and alcohol drinking.
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[2,7,35]. Studies from multiple cancer cells have shown
that the NOXA inhibition or MCL1 overexpression can
dramatically reduce apoptosis and consequently promote
the tumor viability [36-38], which suggests a possible ef-
fect of NOXA-MCL1 axis on susceptibility to cancers. In
consistence with this scenario, we found in current study
that, to some extent, the risk of HPV16-associated
SCCHN, particular oropharyngeal cancer, can be modi-
fied by genetic variants of NOXA and MCL1.
The decrease of SCCHN incidence in recent years ac-
companied by decline of tobacco use has not been
observed for all head and neck cancer sites. However,
the results from the America and European cohort stud-
ies suggested that the oropharyngeal cancer incidence
(especially in younger white populations) has steadily
increased and shown to be associated with the involve-
ment of HPVs, particularly the high risk type 16
[17,19,39-41]. The HPV oncoproteins E6 and E7 may
play decisive roles in HPV16-associated SCCHN by E6-mediated p53 degradation or E7-mediated pRb-E2F deg-
radation and disruption of the p53-related or pRb-
related pathway [23,24].
Interestingly, NOXA and MCL1 are targets of p53 and
E2F, and p53 can affect the expression of its instant
downstream target NOXA by directly binding to the pro-
moter response element. In addition, other common
transcription factors, such as E2F and p73, may also
transcriptively regulate the expression of NOXA as well
as MCL1, through respective response elements in the
promoter regions of NOXA or MCL1 [7,32], thereby
altering susceptibility to SCCHN. It is therefore mechan-
ically conceivable and biologically plausible that HPV16
infection and the functional SNPs in the promoters of
NOXA and MCL1 may jointly affect apoptosis induction,
accordingly altering susceptibility to SCCHN. In agree-
ment with that, we did observe a pronounced modifica-
tion effect of these genetic variants on the risk of
SCCHN, especially oropharyngeal cancer, associated
with HPV16 seropositivity.
Table 4 Joint effect between HPV16 seropositivity and NOXA and MCL1 genotypes on risk of oropharyngeal cancer
stratified by smoking status
HPV16
Serology
Genotypes Never smokers Ever smokers Adjusted OR (95% CI) a
Patients (n = 61) Controls (n = 90) Patients (n = 123) Controls (n = 225) Never smokers Ever smokers
NOXA rs9957673
- CC (Ref.) 19 52 49 137 1.0 1.0
- CT + TT 7 30 24 55 0.7 (0.2-1.8) 1.2 (0.7-2.2)
+ CC 18 7 32 20 8.3 (2.8-24.9) 4.3 (2.4-8.4)
+ CT + TT 17 1 18 13 50.6 (6.1-422.0) 4.1 (1.9-9.2)
P trend = 0.001 P trend = 0.004
NOXA rs4558496
- TT (Ref.) 19 57 47 131 1.0 1.0
- TG+GG 7 25 26 61 0.7 (0.2-2.0) 1.2 (0.7-2.1)
+ TT 26 7 29 21 13.4 (4.7-37.8) 4.0 (2.0-7.7)
+ TG+GG 9 1 21 12 21.9 (2.5-192.6) 4.7 (2.1-10.5)
P trend = 0.008 P trend = 0.002
MCL1 rs3738485
- GG+GT (Ref.) 20 66 61 149 1.0 1.0
- TT 6 16 12 43 1.4 (0.5-4.3) 0.7 (0.3-1.4)
+ GG+GT 27 7 34 30 15.4 (5.5-43.6) 2.8 (1.6-5.1)
+ TT 8 1 16 3 28.0 (3.2-246.6) 12.1 (3.4-43.3)
P trend< 0.001 P trend = 0.003
MCL1 rs3738485
- GG+GC (Ref.) 20 65 61 147 1.0 1.0
- CC 6 17 12 45 1.3 (0.4-4.1) 0.6 (0.3-1.3)
+ GG+GC 27 7 34 29 15.3 (5.4-43.5) 2.9 (1.6-5.2)
+ CC 8 1 16 4 27.7 (3.1-244.7) 8.8 (2.8-27.8)
P trend< 0.001 P trend = 0.008
a ORs were adjusted for age, sex, and alcohol drinking.
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joint effects. In a very recent study, by blocking HPV
E6-mediated p53 degradation to activate the transcrip-
tion of NOXA, RITA (a small-molecule reactivation of
p53 and induction of tumor cell apoptosis) induced
apoptosis in multiple cancer cells containing HPV16 and
substantially suppressed the growth of cervical carcin-
oma xenografts in vivo [29]. Not only the E6 oncopro-
tein, but the E7 oncoprotein can also interact with
NOXA. By disrupting pRb-E2F complexes, the expres-
sion of HPV16 E7 protein up-regulates the NOXA ex-
pression, whereas, the binding of E2F to the NOXA
promoter results in a significant reduction of NOXA-
mediated apoptosis [42], suggesting that HPV E7 may
indeed deregulate the NOXA expression. In addition,
HPV E6- or E7-transfection can significantly up-regulate
the expression of MCL1, therefore promoting lung
tumor cell progression through PI3K pathway [30,31].
These data suggest a possibility that, by deregulating
apoptosis and inferring tumor growth, HPV16 infectionmay alter the progress of NOXA-MCL1 axis-mediated
carcinogenesis through both p53- dependent and inde-
pendent mechanisms. Indeed, we observed in current
study that the risk associated with the joint effects be-
tween HPV16 seropositivity and variants of NOXA and
MCL1 dramatically increased for SCCHN at the oropha-
ryngeal (HPV-related) site but not at non-oropharyngeal
(HPV-unrelated) sites. Although our study implied sig-
nificant trends of effect modification, we did not have
adequate power to detect the interaction.
In consistence with our previously published studies in
which HPV16 and genetic variants of p53 pathway
genes, such as p53 or MDM2, may have interactive
effects on risk of oropharyngeal cancer, particularly in
never smokers and never drinkers [27,28], we also found
in current study more pronounced modification effects
of NOXA and MCL1 variants on the risk associated with
HPV16 seropositivity for oropharyngeal cancer, particu-
larly in never smokers and never drinkers. In addition,
when the subjects were dichotomized by the mean age
Table 5 Joint effect between HPV16 seropositivity and NOXA and MCL1 genotypes on risk of oropharyngeal cancer
stratified by drinking status
HPV16
Serology
Genotypes Never drinkers Ever drinkers Adjusted OR (95% CI) a
Patients (n = 36) Controls (n = 90) Patients (n = 148) Controls (n = 225) Never drinkers Ever drinkers
NOXA rs9957673
- CC (Ref.) 14 57 54 132 1.0 1.0
- CT + TT 3 24 28 61 0.5 (0.1-1.8) 1.2 (0.7-2.0)
+ CC 9 5 41 22 8.1 (2.2-29.5) 4.3 (2.3-8.0)
+ CT + TT 10 4 25 10 12.7 (3.2-50.0) 5.9 (2.6-13.3)
P trend = 0.015 P trend = 0.001
NOXA rs4558496
- TT (Ref.) 9 56 57 132 1.0 1.0
- TG+GG 8 25 25 61 1.8 (0.6-5.4) 1.0 (0.6-1.7)
+ TT 16 7 39 21 15.4 (4.8-49.2) 4.1 (2.2-7.7)
+ TG+GG 3 2 27 11 12.9 (1.7-99.5) 5.4 (2.5-11.6)
P trend = 0.019 P trend = 0.001
MCL1 rs9803935
- GG+GT (Ref.) 12 65 69 150 1.0 1.0
- TT 5 16 13 43 1.8 (0.5-5.8) 0.7 (0.3-1.4)
+ GG+GT 16 9 45 28 11.7 (3.9-34.7) 3.3 (1.9-5.8)
+ TT 3 NA 21 4 NA 10.8 (3.5-33.0)
P trend = 0.002 P trend = 0.001
MCL1 rs3738485
- GG+GC (Ref.) 12 63 69 149 1.0 1.0
- CC 5 18 13 44 1.6 (0.5-5.1) 0.7 (0.3-1.3)
+ GG+GC 16 9 45 27 11.4 (3.8-34.1) 3.4 (1.9-6.0)
+ CC 3 NA 21 5 NA 8.6 (3.1-23.9)
P trend = 0.760 P trend = 0.001
a ORs were adjusted for age, sex, and tobacco smoking.
Zhou et al. BMC Cancer 2012, 12:159 Page 8 of 10
http://www.biomedcentral.com/1471-2407/12/159of the controls, we observed more apparent joint effects
in younger, than older subjects. Though the mechanism
is unclear, many researchers recently documented an ap-
parent increase of incidence of HPV-related oropharyn-
geal cancer, particularly in young adults, perhaps due to
distinct changes in sexual behaviors [43,44]. To the best
of our knowledge, the current study is the first to evalu-
ate the association between polymorphisms in the pro-
moter region of NOXA and MCL1 and risk of SCCHN,
as well as the joint effects between the genetic variants
and HPV16 infection in the etiology of SCCHN.
However, there are several limitations in our present
study. Firstly, although our results suggest a potential ef-
fect on SCCHN risk associated with HPV16, the under-
lying mechanism of NOXA and MCL1 in the
development of SCCHN is still unclear. Thus future
studies are needed to focus on how these polymorph-
isms affect functional changes of the two genes. Sec-
ondly, the HPV16 serology assay used in our study could
test the pre-exposure status but could not define theaccurate infected organs or determine if the viral expos-
ure took place before or after tumor development.
Therefore, with this uncertainty applied to both the
cases and controls, possible false-negative HPV16 cases
might result in misclassification of the HPV16 status.
However, the use of serology assay allowed for the inclu-
sion of a cancer-free control group. Additionally, the
relative small sample size could not provide enough stat-
istical power for further stratified analysis or interaction
analysis; thus we cannot exclude the possibility that our
results could be by chance. Finally, we cannot deduce
similar conclusions with certainty to other ethnic popu-
lations, because our study included only non-Hispanic
white participants.
Conclusions
We found that putatively functional polymorphisms of
NOXA and MCL1 may modify the risk of SCCHN asso-
ciated with HPV seropositive, especially the risk of oro-
pharyngeal cancer among never smokers, never drinkers




Genotypes Age≤ 58 Age> 58 Adjusted OR (95% CI) a
Patients (n = 116) Controls (n = 145) Patients (n = 68) Controls (n = 170) Age≤ 58 Age>58
NOXA rs9957673
- CC (Ref.) 39 89 29 100 1.0 1.0
- CT + TT 15 38 16 47 0.9 (0.5-2.0) 1.2 (0.6-2.5)
+ CC 36 14 14 13 6.4 (3.0-13.6) 4.0 (1.7-9.8)
+ CT + TT 26 4 9 10 14.9 (4.7-46.6) 3.6 (1.3-10.0)
P trend< 0.001 P trend = 0.077
NOXA rs4558496
- TT (Ref.) 36 90 30 98 1.0 1.0
- TG+GG 18 37 15 49 1.2 (0.6-2.4) 1.0 (0.5-2.1)
+ TT 38 11 17 17 9.5 (4.2-21.2) 3.5 (1.6-7.9)
+ TG+GG 24 7 6 6 8.2 (3.2-21.3) 3.9 (1.1-13.8)
P trend< 0.001 P trend = 0.222
MCL1 rs9803935
- GG+GT (Ref.) 44 102 37 113 1.0 1.0
- TT 10 25 8 34 0.9 (0.4-2.0) 0.8 (0.3-1.8)
+ GG+GT 42 17 19 20 5.9 (3.0 -11.8) 3.3 (1.6-8.0)
+ TT 20 1 4 3 47.2 (6.1 -368.2) 3.9 (0.8-19.0)
P trend< 0.001 P trend = 0.338
MCL1 rs3738485
- GG+GC (Ref.) 44 100 37 112 1.0 1.0
- CC 10 27 8 35 0.8 (0.4-1.9) 0.7 (0.3-1.7)
+ GG+GC 42 16 19 20 6.2 (3.1-12.5) 3.3 (1.5-7.0)
+ CC 20 2 4 3 22.7 (5.0-103.5) 3.8 (0.8-18.7)
P trend< 0.001 P trend = 0.270
a ORs were adjusted for age, sex, tobacco smoking and alcohol drinking.
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http://www.biomedcentral.com/1471-2407/12/159and younger individuals. Regardless of the mechanism,
our results implied that a potential joint effect among
NOXA, MCL1 variants and HPV16 seropositivity may
contribute the SCCHN risk. The identification of popu-
lation subgroups at higher risk provide evidence that
HPV-targeting treatment may help benefit SCCHN.
However, well-designed studies with larger sample sizes
in different ethnic populations are needed to validate
our findings.
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